Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

The FDA just approved a new nasal application for allergy medicine. Pennsylvania law allows for school nurses to train other ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

Corticosteroid nasal sprays. You can use them long-term to ... for as many as 2 to 5 years. In 2014, the FDA approved sublingual immunotherapy for treatment of grass and ragweed pollens.

Please provide your email address to receive an email when new articles are posted on . Atzumi is the first dihydroergotamine-based nasal powder approved for migraine treatment in adults.

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray ... 15 and 30kg. Approved by the US Food and Drug Administration (FDA) in March 2025, the spray is now ...

Schroeder, MD, MEng In February, the FDA approved ... your allergies have exploded, let’s bring out the cleanup committee,” which includes antihistamine, nasal sprays and eye drops.